Latest News

11th September 2017

Centauri Therapeutics receives Innovate UK Biomedical Catalyst Award

Centauri Therapeutcs

  • Funding will be used to develop the Company’s Alphamer technology to target antibacterial resistance
  • The UK’s innovation agency will contribute up to £945K towards the project

London and Kent, UK, 11 September 2017:  Centauri Therapeutics Ltd (Centauri), a biotechnology company focused on the treatment of infectious diseases and cancer, announced today that it has been awarded up to £945,000 under Innovate UK’s Biomedical Catalyst (BMC) programme. Alongside backing from the Company’s investors, this award from the UK’s innovation agency will co-fund research focused on antimicrobial resistance. The project aims to generate a clinical candidate drug against Gram-negative bacteria, which are a major cause of mortality in hospital-acquired pneumonias, using the Company’s Alphamer™ technology.

Bacteria are continually evolving to resist new antibiotics, meaning new medicines are required to target novel drug-resistant strains and deliver effective therapies to patients. Centauri plans to develop an innovative treatment for patients suffering from infections caused by these resistant bacteria. Using the Company’s Alphamer drug mechanism, chemically synthesised molecules will redirect pre-existing antibodies to pathogens in a specific manner that elicits an immune response. This immune response will mediate destruction of the bacteria to clear the infection, while working in conjunction with existing antibiotics to reduce the dose and duration of therapy. Unlike traditional vaccines, this approach aims to treat infected patients and has the potential to elicit a broader immune response than monoclonal antibodies alone.

Dr Mike Westby, Director and CEO of Centauri Therapeutics, commenting on the award said: “The lack of new antibiotics combined with increasing incidence of bacterial resistance in the clinic has been termed ‘the perfect storm’ and there is an urgent need for innovative methods and efficacious therapies. The BMC Award is a significant recognition of Centauri’s scientific expertise and demonstrates the UK government’s confidence in our team’s ability to combat antibacterial resistance and deliver novel treatments for patients.”

Total costs for the project titled ‘Optimisation of antibody recruiting molecules as immunotherapeutics’ are estimated at £1.35M. The co-funding from Innovate UK will cover up to 70% of this, with Centauri’s investors supporting the remaining 30% of the project costs over a two-year period.

ENDS

 

Media enquiries

Lorna Cuddon, Zyme Communications

This email address is being protected from spambots. You need JavaScript enabled to view it.

+44 (0)7811 996 942

 

About Centauri Therapeutics Ltd www.centauritherapeutics.com

Centauri Therapeutics is a UK-based biotechnology company focused on the discovery and development of novel molecules targeting life threatening diseases.  Centauri is pursuing anti-bacterial opportunities on its own and immune-oncology opportunities through its joint venture with Horizon Discovery plc, Avvinity Therapeutics (Avvinity.com).

Centauri Therapeutics’ Executive team is led by Mike Westby, Chief Executive Officer (previously Pfizer, Roche) and Stuart Lawson, Chief Financial Officer (CEO of the private investment group Animatrix Capital LLP, and previously KPMG). Clive Dix is Non-Executive Director and Chairman of the Board (CEO of C4X Discovery and previously Convergence Pharmaceuticals, PowderMed, PowderJect, Glaxo Wellcome). Jonathan Synett is Managing Director of NCL Ventures, a specialist investment management firm focussing on high growth technology companies.

The company is backed by private investors and a strategic investment from a regional investment fund (Discovery Park Technology Investment Fund).

Centauri Therapeutics is based at Discovery Park, Kent.

 

About Alphamer™ Technology

The Alphamer™ technology is based on "programmable immunity" in which chemically synthesised molecules redirect naturally occurring antibodies to selected pathogens to fight the infection. The molecules have two distinct parts: one end binds a cell-surface target on the pathogen using an aptamer whereas the other end presents specific epitopes that attach to the circulating antibodies. It has been demonstrated that Alphamers have the potential to redirect pre-existing antibodies to bacteria in a specific manner and trigger an immediate antibacterial immune response, so clearing the infection.

 

About Innovate UK and the Biomedical Catalyst 

Innovate UK is the UK’s innovation agency. It works with people, companies and partner organisations to find and drive the science and technology innovations that will grow the UK economy. For further information visit www.innovateuk.gov.uk

The Biomedical Catalyst (BMC) is a unique partnership between the MRC and Innovate UK, providing responsive and effective support to the most innovative life sciences opportunities regardless of scientific approach. The BMC aims to de-risk innovative science and commercialise ideas arising out of academia and industry helping UK SMEs to develop into competitive and sustainable organisations.  This accelerates the progress of novel products to market, facilitates onward investment and bridges “the valley of death”.

 


23rd August 2017

Centauri Therapeutics Ltd to attend The World Anti-Microbial Resistance Congress 2017

Centauri's CEO Mike Westby will be attending the World Anti-Microbial Resistance Congress in Washington from 14 - 15 September 2017. Please click on the banner below for more information.

 

World Anti-Microbial Resistance Congress

 


25th May 2017

Centauri Therapeutics Ltd revealed in the Future List of companies changing the way people live and work in Kent

Centauri has been revealed in the Future List as one of the twenty five companies changing the way people in Kent live and work. Selected by a team of expert judges, Centauri has been chosen as one of the group of firms that are developing and selling innovative products and services that are transforming lives for the better. Please click on the banner below for more information.

 


10th April 2017

Centauri Therapeutics Ltd to attend ECCMID and present at the event's Pipeline Corner 

Centauri's CEO Mike Westby and Microbiologist Emma Leire will be attending the 27th European Congress of Clinical Microbiology and Infectious Diseases in Vienna from 22 - 25 April 2017, where they have been invited to present an overview of the company's R & D pipelines and recent advances,  in the event's Pipeline Corner.  Please click on the banner below for more information 

ECCMID 

 


20th February 2017

Centauri Therapeutics Ltd closes £2.5m fundraising

Centauri Therapeutcs

  • Second tranche of seed financing secured, sufficient to develop first lead candidate through to proof of principle
  • £1.2m raised in oversubscribed completion of funding round

London and Kent, UK, 20th February 2017: Centauri Therapeutics Ltd, a biotechnology company focused on the treatment of infectious diseases and cancer, announced today that it has secured an additional £1.2m in funding to complete the seed round, the first tranche of which was raised in January 2016. The participants in the second tranche included existing investors and several new private investors. The funds raised will be used to take the Company’s first Alphamer drug candidate for anti-infective therapies through to preclinical proof of concept, a significant value inflection point in the program development, whilst progressing two other anti-bacterial candidates in parallel.  

Separately, Centauri is also actively progressing immune-oncology targets through Avvinity Therapeutics, its joint venture with Horizon Discovery Group plc, in which Horizon will invest up to £5.3 million over two tranches with the first tranche of £2.5m already committed.  Centauri’s focus on anti-microbial resistance and immuno-oncology medicines are priority markets for the worldwide healthcare agenda, which are forecast to reach a combined total of £100bn by 2020.

The Alphamer technology is based on "programmable immunity" in which chemically synthesised molecules redirect naturally occurring antibodies to selected targets. The molecules have two distinct parts: one end binds a cell-surface marker on the target (bacterial or tumour cell) using an aptamer, whereas the other end presents specific epitopes that attach to the circulating antibodies. It has been demonstrated that Alphamers have the potential to redirect pre-existing antibodies to the target in a specific manner and trigger an immediate immune response, so removing the target. Centauri Therapeutics’ assets include specific leads and platform chemistry that is protected by strong IP and a family of granted patents and applications.

Mike Westby, CEO of Centauri Therapeutics, commented: “Progress at Centauri on both our anti-infectives and immuno-oncology programmes has been very positive, with the development and optimisation of candidate Alphamers running well ahead of schedule.  I am delighted with the continued support from our existing investors and I welcome our new investors to Centauri.”

ENDS

For more information please contact:

Lorna Cuddon, Zyme Communications

This email address is being protected from spambots. You need JavaScript enabled to view it.

+44 (0)7811 996 942

About Centauri Therapeutics Ltd (www.centauritherapeutics.com)

Centauri Therapeutics is a UK-based biotechnology company focused on the discovery and development of novel molecules targeting life threatening diseases.  Centauri is pursuing anti-bacterial opportunities on its own and immune-oncology opportunities through its joint venture with Horizon Discovery plc, Avvinity Therapeutics (Avvinity.com).

Centauri Therapeutics’ Executive team is led by Mike Westby, Chief Executive Officer (previously Pfizer, Roche) and Stuart Lawson, Chief Financial Officer (CEO of the private investment group Animatrix Capital LLP, and previously KPMG). Clive Dix is Non-Executive Director and Chairman of the Board (CEO of C4X Discovery and previously Convergence Pharmaceuticals, PowderMed, PowderJect, Glaxo Wellcome).

The company is backed by private investors and a strategic investment from a regional investment fund (Discovery Park Technology Investment Fund).

Centauri Therapeutics is based at Discovery Park, Kent.

 


1st February 2017

Centauri Board welcomes Jonathan Synett

Centauri Therapeutics Ltd is delighted to announce that Jonathan Synett has joined the Board of Directors.  Jonathan has extensive experience working with and investing in early stage, high growth businesses. Centauri extends warm thanks to Jerry Biggs who has recently stepped down as Director to pursue other ventures.

 
 

14th November 2016

Genesis 2016 Conference

Centauri Therapeutics Ltd will be attending the Genesis 2016 conference, where the overall theme will be "The Science, Technology and Business of 21st Century Biomedical Innovation".  The conference agenda will showcase success in the application of biomedical research, innovative technologies and leading edge business strategies in order to deliver effective benefits to patients globally.  For more information on the event, please click on the banner below. 

 

Genesis 2016

 


14th October 2016

Dr Mike Westby to speak at the Buck Institute for Research's Fall Conference. 

Buck Institue

 

The Buck Institute For Research on Aging will be holding their Fall Conference in Split Croatia, this weekend, 15th and 16th October. The conference theme is "Aging: Is Time Relative? An Adriatic Perspective" and Dr Mike Westby has been invited to speak at the event.  He will be delivering his speech entitled "Redirecting Host Immunity As A Therapeutic Approach For Diseases Caused By Anti-Microbial Resistant (AMR) Pathogens: Lessons From Cancer" to an audience of 50 influential individuals in business, finance, investments and philanthropy from around the world.  For more information on the work carried out by the The Buck Institute please click on the link.

 


13th October 2016

Centauri Therapeutics and the Horizon Discovery Group shortlisted for award  

Scrip awards

The 12th Annual Scrip Awards will take place at the Grosvenor House Hotel in London on 30th November 2016.  Centauri Therpeutics are delighted to announce that they have been shortlisted in the category of Best Partnership Alliance, along with the Horizon Discovery Group, for their immuno-oncology joint venture, Avvinity Therapeutics.  Please click here for more details of the event. 

 


28 September 2016

UK Bioscience Forum 2016

Representatives from Centauri Therapeutics will be attending the award winning UK Bioscience Forum 2016, which will take place on 20th October, at The Royal College of Surgeons in London.  The bioscience community will be gathering together for a day of partnering, networking and to enjoy presentations, discussions and debates.  For more details of the event, please click on the banner below 
  

Bio Science Forum 2016

 


23 September 2016

UN Pledges to fight the biggest threat to modern medicine - Antibiotic resistant bacteria

The 193 countries on the United Nations have agreed a landmark declaration to rid the world of drug-resistant infections.  Experts say that this international commitment could prevent upto 700,000 deaths a year.  Both BBC News and The Guardian have published articles on the declaration. Click on the links to read the items in full. 

 


12 September 2016

Centauri Therapeutics to attend OBN BioTuesday Antibiotic Resistance Event 

OPN Logo

Dr Mike Westby and Nick Higgins will be attending the meeting, to be held in Cambridge on 27th September. Antibiotic resistance is a threat that is becoming increasingly prevalent, leading to untreatable bacterial infections that may develop into a real and present danger to society. High quality presenters and panellists will help debate the challenge and opportunities in this field.  For more details of the event please click here

 


24 August 2016

Lord Heseltine visits the Discovery Park

Lord Heseltine was welcomed to The Discovery Park by representatives of companies based within the site, including the CEO of Centauri Therapeutics, Dr Mike Westby. 

Dr Mike Westby commented:

“Meeting Lord Heseltine and his team was a great opportunity to share my experience of running life science research at Sandwich.

“Discovery Park is a living example of how quickly a purpose-built Pharma R&D site can be evolved and repurposed to support tenants and encourage new investment.

“Only five years ago I was one of 2,400 Pfizer employees on a single occupancy site; today I lead one of over 150 different businesses in a thriving and diverse business park.”   

For more information on Lord Heseltine's visit, read the press release published on the Discovery Park website. 

 


22 August 2016

Centauri Therapeutics to attend Biotech and Money Assembly and Awards Gala Dinner 

Biotech logo

Centauri Therapeutics Limited will be among 275 people attending a gala dinner on 6th September, hosted by Biotech and Money, an influential community of senior life science decision makers.  The event will be celebrating the UK's funding, finance and investment successes in the sector over the last 12 months, with award winners and runners up in 7 categories being decided on the night, by live vote. 

Award catergories

award logos biotech

 

 


15 July 2016

Centauri Therapeutics welcomes industrial placement student 

This month Centauri welcomes industrial placement student Ben McNeilly, a chemistry undergraduate student from St. Andrews University. As an Enterprise Plus company with the RSC, Centauri was awarded a highly sought after one-year placement grant for an undergraduate student. Ben joins Centauri's industry experienced chemistry team to contribute to the novel linker and Alphamer platform. 


 8 July 2016

SE East Business interview Dr Mike Westby

South East Business, the magazine for leaders and business executives across Kent, Surrey and Sussex, has published an interview with Centauri CEO Mike Westby and co-director and investor, Jerry Biggs, CEO of NCL

http://www.southeastbusiness.com/section/features/race-against-time

 


 8 July 2016

Centauri Therapeutics extends research partnership with Peakdale Molecular

Peakdale Molecular Limited, a UK-based provider of drug discovery services to the pharmaceutical and biotech industries has signed an agreement to extend its research collaboration with Centauri Therapeutics, a UK based biotechnology company focussed on the discovery and development of novel molecules targeting life threatening diseases. Peakdale provides synthetic and analytical chemistry expertise for the continued development of Centauri’s Alphamer platform.

Alphamer technology is based on programmable immunity in which chemically synthesised molecules redirect naturally occurring antibodies to selected pathogens to fight infection. The molecules have two distinct parts: one end binds a cell-surface target on the pathogen using an aptamer, whereas the other end presents specific epitopes that attach to circulating antibodies. It has been demonstrated that Alphamers have the potential to redirect pre-existing antibodies to bacteria in a specific manner and trigger an immediate antibacterial immune response, so clearing the infection.

Centauri acquired the Alphamer platform following the publication of a successful preclinical proof of principle study and continues to build the platform and drug discovery expertise necessary to exploit the exciting new approach. Centauri has been working closely with Peakdale’s experience team of chemists to synthesise and analyse the optimal linker for each bioconjugated Alphamer/aptamer.

Commenting on Centauri’s collaboration with Peakdale, Dr Mike Westby, CEO of Centauri said: “We have been delighted with the rapid progress made in the development of our Alphamer platform, with Peakdale chemists making a significant contribution to meeting our ambitious and demanding scientific objectives. We look forward to continuing to work with Peakdale in this new phase of the project.

Dr Paul Doyle, COO of Peakdale commented: “Centauri is operating in an exciting area in which expertise in complex synthetic and analytical chemistry is a key component. We are delighted that the decades of experience Peakdale has acquired combined with our partnership approach has demonstrated the value working with Peakdale can provide.”

http://www.manufacturingchemist.com/news/article_page/Centauri_Therapeutics_extends_research_partnership_with_Peakdale_Molecular/119562 

About Centauri Therapeutics Ltd

Centauri Therapeutics is a UK-based biotechnology company focused on the discovery and development of novel molecules targeting life threatening diseases.

Centauri Therapeutics has established a core R&D facility at Discovery Park in Sandwich, Kent, with an experienced team of industry scientists focused on discovery, optimisation and development of novel Alphamers targeting acute hospital acquired infections.

For more information about Centauri visit www.centauritherapeutics.com

About Peakdale Molecular Ltd

Peakdale Molecular (part of the Concept Life Sciences Group) is a leading UK-based provider of drug discovery services to the pharmaceutical, biotech, diagnostics and materials sciences.

Peakdale is renowned for skills in problem-solving and open communications, and our scientists pride themselves in seizing the initiative, providing energy, skill and creativity toward the project objectives. Peakdale Molecular operates on two sites, from our headquarters in the Peak District and at Discovery Park located at Sandwich, Kent.

For more information about Peakdale Molecular visit www.peakdale.co.uk

Notes to editors:

The Concept Life Sciences Group was created following the acquisition of Peakdale Molecular Limited, Scientific Analysis Laboratories Limited, Resource & Environmental Consultants Limited, CXR Biosciences and Agenda1 Analytical Services. The Group offers a comprehensive range of services to clients in the pharmaceutical, biotech, agrochemical, petrochemical, chemical, food, environmental and consumer industries.

For media information contact Sarah Roberts, Vane Percy & Roberts, +44 (0)1737 821890,  This email address is being protected from spambots. You need JavaScript enabled to view it.
For more information about Peakdale Molecular contact Gordon Woodrow, This email address is being protected from spambots. You need JavaScript enabled to view it.
For more information about Centauri Therapeutics contact Mel Glossop, This email address is being protected from spambots. You need JavaScript enabled to view it.

 


3 May 2016

Centauri Therapeutics have joined the BEAM Alliance, along with other companies developing anti-infectives: http://beam-alliance.eu/


2 March 2016

Centauri Therapeutics Limited Forms Joint Venture with Horizon Discovery Group plc

Creating Differentiated New Player in the Rapidly growing

Immuno-Oncology Market

  • Newly formed company Avvinity Therapeutics will be jointly managed by Centauri and Horizon, via its Research Biotech business
  • Joint venture creates a differentiated new player in the rapidly growing immuno-oncology market, currently valued at £25 billion
  • Avvinity will have exclusive rights in oncology to use Alphamer therapeutic platform,invented by a Nobel Laureate and developed by Centauri
  • Horizon to invest up to £5.3 million, with an initial outlay of £2.5 million, in a joint venture to identify novel immuno-oncology therapeutics
  • Horizon will contribute its gene editing technology platform and oncology expertise and will also benefit from service revenues from the joint venture
  • Formation of the joint venture represents a strategic move by Horizon to capture the upside potential of its IP, platform technologies and capabilities in immuno-oncology, synthetic lethality and cell therapy based therapeutics.

London and Kent, UK, 2 March 2016: Centauri Therapeutics Limited (“Centauri”), a UK-based biotechnology company focused on the discovery and development of novel molecules targeting life-threatening infectious diseases has formed an immuno-oncology joint venture, Avvinity Therapeutics (“Avvinity”), with Horizon Discovery Group plc (LSE: HZD) ("Horizon" or “the Company”), the leading international gene editing company.

Avvinity will combine Centauri’s Alphamer technology to provide a powerful and proprietary platform to discover and develop novel immuno-oncology therapeutics, for both solid tumours and leukaemias with Horizon’s gene editing, immunology, oncology and drug discovery capabilities. Avvinity will be targeting an immuno-oncology market currently worth £25 billion per year and expected to grow to approximately £50 billion per year by 2020.

Dr. Mike Westby, Chief Executive Officer of Centauri Therapeutics Limited, commented: Alphamers are an entirely novel way to target disease and represent an exciting new approach for recruitment of host immunity. At Centauri we have invested to build the Alphamer platform and assembled the drug discovery expertise necessary to exploit the platform in infectious diseases. Through this joint venture with Horizon, we look forward to applying our combined know-how and capabilities to develop Alphamers as important new immuno-oncology medicines, particularly for cancer indications that have proven intractable to date.”

For further information, please see the press release published 2nd March 2016 or visit the Avvinity website at www.avvinity.com.

 


18 January 2016                        

Centauri Therapeutics Ltd to Develop Novel Anti-Infective Therapeutics

 

  • Company has acquired Alphamer immuno-therapeutics platform technology
  • Initially focusing on anti-infective indications
  • Dr Clive Dix appointed as Chairman
  • Secured initial tranche of £3M financing, sufficient to develop first lead candidate

 

London and Kent, UK, 18 January 2016: Centauri Therapeutics Ltd, a biotechnology company focused on the treatment of infectious diseases, announced today that it has acquired the Alphamer technology for drug discovery and development from Altermune Technologies LLC. Centauri Therapeutics acquired full rights to patents, proprietary compounds, know-how and collaboration/licence agreements from Altermune in exchange for an undisclosed fee.

The company has also announced that it has appointed Dr Clive Dix as Chairman and secured the first tranche of a £3M raise to develop its first lead candidate. The funding will be used to develop its first lead Alphamers against anti-microbial resistant (AMR) pathogens, which pose an increasing threat to human health. Investors include Animatrix Capital LLP, a regional investment fund, and private investors.

Centauri Therapeutics’ decision to acquire the Alphamer platform was made following the publication of a successful preclinical proof of principle study by Professor Victor Nizet, a professor at UCSD, California and a leading academic in the field of antimicrobial immunity.

Clive Dix has more than 25 years’ experience in the life sciences industry and is one of the UK’s leading pharma and biotech entrepreneurs. Clive was formerly co-founder and Chief Executive of Convergence Pharmaceuticals Ltd., acquired by Biogen Idec in 2015 in a deal worth up to $675 million. Previously, he was a founder and CEO of PowderMed Ltd, acquired by Pfizer in 2006; and Chairman of Auralis Ltd where he managed a successful US trade sale. Before that he was a main Board Director of PowderJect Pharmaceuticals plc until its acquisition by Chiron in 2003. 

Centauri Therapeutics has established a core R&D facility at Discovery Park in Sandwich, Kent, with an experienced team of industry scientists focused on discovery, optimisation and development of novel Alphamers targeting acute hospital acquired infections.

Mike Westby, CEO of Centauri Therapeutics, commented: “The emergence and rapid global spread of AMR pathogens means that there is a large potential market to treat life-threatening intractable diseases. Alphamers are chemically synthesised molecules designed to redirect the body’s own immune system to more effectively fight infection. As well as the new financing announced today we are also proud to announce the appointment of Clive Dix as our Chairman. Clive’s experience in successfully developing therapeutic platform technologies will be invaluable.”

Clive Dix, Chairman of Centauri Therapeutics, said: “The Alphamer platform technology is a unique opportunity to assemble well-characterised building blocks to produce novel and IP-protected medicines. Centauri Therapeutics has assembled a team of industry-experienced R&D scientists guided by a proven leadership.”

ENDS

 

For more information please contact:

Lorna Cuddon, Zyme Communications

This email address is being protected from spambots. You need JavaScript enabled to view it.

+44 (0)7811 996 942

About Centauri Therapeutics Ltd (www.centauritherapeutics.com)

Centauri Therapeutics is a UK-based biotechnology company focused on the discovery and development of novel molecules targeting life threatening diseases.

The Alphamer technology is based on "programmable immunity" in which chemically synthesised molecules redirect naturally occurring antibodies to selected pathogens to fight the infection. The molecules have two distinct parts: one end binds a cell-surface target on the pathogen using an aptamer whereas the other end presents specific epitopes that attach to the circulating antibodies. It has been demonstrated that Alphamers have the potential to redirect pre-existing antibodies to bacteria in a specific manner and trigger an immediate antibacterial immune response, so clearing the infection. Centauri Therapeutics’ assets include specific leads and platform chemistry that is protected by strong IP and a family of granted patents and applications.

Centauri Therapeutics’ Executive team is led by Mike Westby, Chief Executive Officer (previously Pfizer, Roche) and Stuart Lawson, Chief Financial Officer (CEO of the private investment group Animatrix Capital LLP, and previously KPMG). Clive Dix is Non-Executive Director and Chairman of the Board (previously Convergence Pharmaceuticals, PowderMed, PowderJect, Glaxo Wellcome).

The company is backed by private investors and a strategic investment from a regional investment fund (Discovery Park Technology Investment Fund).

Centauri Therapeutics is based at Discovery Park, Kent. For more information about the company please visit www.centauritherapeutics.com


·         will be used to develop the Company’s Alphamer technology to target antibacterial resistance